Campbell & Co Investment Adviser’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-6,347
Closed -$427K 1203
2025
Q4
$427K Sell
6,347
-53,056
-89% -$3.57M 0.02% 881
2025
Q3
$4.36M Buy
59,403
+50,250
+549% +$3.34M 0.33% 45
2025
Q2
$476K Sell
9,153
-92,855
-91% -$5.28M 0.03% 804
2025
Q1
$6.51M Buy
102,008
+63,102
+162% +$3.67M 0.5% 14
2024
Q4
$1.86M Buy
38,906
+7,628
+24% +$391K 0.14% 197
2024
Q3
$1.79M Buy
31,278
+23,313
+293% +$1.34M 0.13% 222
2024
Q2
$417K Sell
7,965
-25,593
-76% -$1.12M 0.04% 717
2024
Q1
$1.37M Buy
33,558
+16,189
+93% +$607K 0.12% 268
2023
Q4
$642K Buy
17,369
+1,904
+12% +$71.7K 0.06% 590
2023
Q3
$591K Buy
+15,465
New +$634K 0.07% 445
2023
Q2
Sell
-34,193
Closed -$1.31M 984
2023
Q1
$1.31M Buy
34,193
+20,673
+153% +$970K 0.24% 92
2022
Q4
$769K Sell
13,520
-7,204
-35% -$369K 0.18% 158
2022
Q3
$819K Buy
20,724
+4,382
+27% +$194K 0.19% 173
2022
Q2
$719K Buy
+16,342
New +$707K 0.19% 160
2021
Q4
Sell
-11,065
Closed -$450K 691
2021
Q3
$450K Buy
+11,065
New +$463K 0.15% 248
2021
Q2
Sell
-5,815
Closed -$242K 593
2021
Q1
$242K Buy
5,815
+800
+16% +$36.5K 0.15% 297
2020
Q4
$214K Sell
5,015
-6,500
-56% -$234K 0.13% 346
2020
Q3
$303K Sell
11,515
-3,369
-23% -$93.8K 0.23% 177
2020
Q2
$399K Buy
+14,884
New +$336K 0.5% 49
2020
Q1
Sell
-113,958
Closed -$2.02M 231
2019
Q4
$2.02M Buy
+113,958
New +$1.97M 0.62% 9
2013
Q3
Sell
-42,166
Closed -$335K 294
2013
Q2
$335K Buy
+42,166
New +$269K 0.06% 250

Other funds holding HALO

Campbell & Co Investment Adviser's HALO Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Halozyme (HALO) in Q1 2026, closing a stake of 6,347 shares — an estimated $427K sold.

Campbell & Co Investment Adviser first reported a position in HALO in Q2 2013 and held it in 21 quarters. The position peaked at $6.51M in Q1 2025. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining Halozyme position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 6,347 Halozyme shares in Q1 2026, an estimated $427K.
  • Campbell & Co Investment Adviser first reported a position in Halozyme in Q2 2013 and held it in 21 quarters.
  • Campbell & Co Investment Adviser's Halozyme position peaked at $6.51M in Q1 2025.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.